« Back to Glossary Index

A vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) used for the treatment of advanced kidney cancer. Votrient works by blocking the development of a new blood supply (angiogenesis) to the tumour, thereby starving the tumour of nutrients and oxygen needed to grow, and interfering with the growth of cancer cells. Votrient is a type of angiogenesis inhibitor. Pazopanib is the chemical (or generic) name of the drug, while Votrient is the brand (or trade) name under which the drug is licensed and sold.

« Back to Glossary Index